Eduardo Castañón Álvarez

Author

Also Known As

E Castanon Alvarez, E Castañón Alvarez, E. Castanon Alvarez, E. Castañón Álvarez, E.C. Álvarez, Eduardo C. Alvarez, Eduardo Castanon Alvarez, Eduardo Castanon Álvarez, Eduardo Castañón Alvarez, Eduardo Castañón Álvarez

111

Publications

304

Citations

H-Index

Concepts

All Affiliations

Clinica Universidad de Navarra University of Toronto Merck & Co., Inc., Rahway, NJ, USA (United States)Yonsei University The Alfred Hospital

About

Eduardo Castañón Álvarez is an author at Clinica Universidad de Navarra specializing in cancer therapeutics, oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	146
2	Immunology	4	4	115
3	Pathology	3	3	101
4	Pharmacology	3	3	48
5	Cancer Epidemiology	3	3	101

Eduardo Castañón Álvarez

Publications

187

Citations

H-Index

Page 1

	Year	Citations
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. Carlos Gomez‐Roca, Eduardo Yáñez, Seock‐Ah Im, Journal of Clinical Oncology OncologyCancer EpidemiologyPd-l1 ExpressionImmunologyTumor Immunity	2021	66
Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v) Ignacio Melero, Eduardo Castañón Álvarez, Morten Mau‐Sørensen, Annals of Oncology	2018	19
LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. Carlos Gomez‐Roca, Eduardo Yáñez, Seock‐Ah Im, Journal of Clinical Oncology Multicohort StudyOncologyCancer EpidemiologyPd-l1 ExpressionImmunology	2021	18
LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort. Hyun Cheol Chung, Zarnie Lwin, Carlos Gomez‐Roca, Journal of Clinical Oncology Cancer EpidemiologyPd-l1 ExpressionGastrointestinal OncologyMedicineAdvanced Gastric Cancer	2021	17
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01. Kristoffer Staal Rohrberg, Mariana Brandão, Eduardo Castañón Álvarez, Journal of Clinical Oncology ImmunologyImmunoeditingCheckpoint InhibitorTigit RoImmunotherapy	2023	17
663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC Carlos Rojas, Rosalyn A. Juergens, Adrian G. Sacher, Annals of Oncology OncologySolid TumorsMedicineImmune Checkpoint InhibitorPharmacotherapy	2023	14
1313MO Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy Benjamin Besse, Antoine Italiano, Sophie Cousin, Annals of Oncology Bispecific AntibodyMedicineImmunologyTumor ImmunityImmune Checkpoint Inhibitor	2023	14
44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC C.I. Rojas, Rosalyn A. Juergens, Adrian G. Sacher, ESMO Open	2024	12
Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy Ana Ezponda, M. Calvo Imirizaldu, Juan P. de‐Torres, Radiología (English Edition)	2020	10

Page 1